
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 74
Selected: 0
NCT ID | Title | ||
---|---|---|---|
NCT02159690 | A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy | ||
NCT04824937 | Telaglenastat + Talazoparib In Prostate Cancer | ||
NCT04343885 | In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy | ||
NCT02300324 | The Bioavailability Of Sulforaphane From Broccoli Soups Study (BOBS) | ||
NCT05766371 | Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | ||
NCT01379742 | Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy | ||
NCT02881242 | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | ||
NCT02582697 | Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours | ||
NCT02499835 | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer | ||
NCT03644303 | Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients. | ||
NCT04116775 | Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. | ||
NCT06171139 | Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer | ||
NCT07002320 | Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer | ||
NCT06616597 | Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer | ||
NCT03358563 | Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer | ||
NCT07050433 | Correlate Biomarkers for the SYNERGY- 201 Study | ||
NCT04457232 | Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation | ||
NCT00156884 | A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer | ||
NCT04716725 | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer | ||
NCT02478125 | Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer | ||
NCT01990196 | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | ||
NCT00953576 | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer | ||
NCT03392428 | A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer | ||
NCT05765500 | RecoverPC: Relugolix vs GnRH Agonist in Quality of Life | ||
NCT06040125 | Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial | ||
NCT05113537 | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | ||
NCT05435495 | Mechanisms of Resistance to PSMA Radioligand Therapy | ||
NCT06046040 | TmPSMA-02 in mCRPC | ||
NCT03492424 | Ablative Therapy in the Management of Prostate Cancer | ||
NCT03276572 | Phase I Trial of 225Ac-J591 in Patients With mCRPC | ||
NCT04447703 | Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study | ||
NCT03957252 | Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer | ||
NCT01417182 | Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer | ||
NCT03007732 | Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT | ||
NCT03532217 | Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer | ||
NCT02856100 | Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer | ||
NCT01950143 | Effect of Sulforaphane on Prostate CAncer PrEvention | ||
NCT01703065 | Cabozantinib in Men With Castration-Resistant Prostate Cancer | ||
NCT03440554 | Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization | ||
NCT05320406 | RElugolix VErsus LeUprolide Cardiac Trial | ||
NCT02025413 | Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method | ||
NCT00744549 | Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance | ||
NCT03805594 | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | ||
NCT05150236 | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | ||
NCT03031821 | Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome | ||
NCT06126731 | Combination Study of Antibiotics With Enzalutamide (PROMIZE) | ||
NCT05041504 | A Web-based Peer Navigation Program for Men With Prostate Cancer | ||
NCT02677376 | Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC | ||
NCT02269982 | Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY | ||
NCT02080650 | Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET) |